NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
Leon, Leticia G.
Narayan, Ravi S.
Tjin Tham Sjin, Robert
Heideman, Daniëlle A.M.
Alfieri, Roberta R.
Heynen, Guus J.
Smit, Egbert F.
Peters, Godefridus J.
- Publisher: Impact Journals LLC
NF-κB | EGFR-T790M | NSCLC | drug-resistance | Research Paper | EMT
mesheuropmc: respiratory tract diseases
The clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations is limited by the emergence of acquired resistance, mostly ascribed to the secondary EGFR-T790M mutation. Selective EGFR-T790M inhi...